Abstract: Objective To evaluate the efficacy and safety of Aidi injection in the treatment of ovarian cancer. Methods The Cochrane Library, MEDLIN E, VIP, CNKI and CBM disc were searched. The quality of included studies was evaluated and meta-analysis was performed for the results of homogeneous studies. Results Three studies involving 201 participants with advanced ovarian cancer were included.All included studies employ means of randomization, but are inadquate in reporting concealment of allocation and blinding.Meta analysis based on included studies showed that response rate of Aidi injection combined with chemotherapy is better than the control group. Median time to progress and median survival time of Aidi injection are both one more month than control group.There was no clinical evidence in reducing adverse effect of chemotherapy. Conclusion Aidi injection is an effective and safe anti-cancer drug. Due to high risk of selection bias and detection bias of included studies, the evidence is not strong enough .Our results required further and larger-scaled RCT trials of the use of Aidi injection in the treatment of ovarian cancer.